Navigation Links
Dartmouth researchers find promising results with local hyperthermia of tumors
Date:3/4/2014

A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock Norris Cotton Center researchers in the journal Nanomedicine: Nanotechnology, Biology and Medicine released online on February 24, 2014.

"The study demonstrates that controlled heating of one tumor can stimulate an immune response that attacks another tumor that has not had the heat treatment," said Steve Fiering, PhD, Norris Cotton Cancer Center researcher and professor of Microbiology and Immunology, and of Genetics at the Geisel School of Medicine at Dartmouth. "This is one way to try to train the immune system to attack metastatic tumors that may not be recognized yet."

Researchers injected iron-oxide nanoparticles into the tumor and then activated those agents with magnetic energy. Researchers were able to activate antigen-presenting dendritic cells in the body's immune system. Dendritic cells somewhat serve as "quarterbacks" for body's immune system by calling for quick coordinated protection against an attack. The "quarterback" cells show the defensive "killer" T cells (CD8+ cells) who to attack and these cells then directly attack tumor cells and send out an alert system to engage other cells in the fight against the cancer. The combination of these two aspects of the immune response reduce risk of recurrence and discourage spreading or metastasis of the cancer. This result was observed in sites close to the primary tumor as well as distant sites. In the experiments conducted as part of this study the primary tumor resisted regrowth for one month following overheating.

The magnetic hyperthermia system used was developed by co-author P. Jack Hoopes, DVM, PhD co-director of Norris Cotton Cancer Center's Nanotechnology Working Group. "It enables very precise control of the heating to keep the temperature at a uniform 43 degrees C for as long as desired," said Fiering. "This precise control was the key to optimal immune stimulation."

The experiment included mouse colon and, melanoma cancers. Tumors responded to the heat by growing more slowly or disappearing completely. A higher temperature was better at eliminating primary tumors that were heat treated, but did not activate the immune system as well to find and attack metastatic tumors. Treatment of larger primary tumors generated a stronger immune response.

In the effort to develop better cancer treatments, the challenge is to find ways to cure metastatic disease. "The use of the immune system through cancer immunotherapy is a very exciting field currently and promises to contribute significantly to elimination of metastatic tumors," said Fiering. "The approach demonstrated is a good new option to be combined with other immunotherapy strategies for cancer therapy."

Standard cancer care involves surgery, but surgeons have few tools to guarantee the removal of every cancer cell, especially when there is unrecognized metastases in other anatomic locations. An approach like local hyperthermia one day might be used to kick start the immune system to ward off any cancer cells not removed by surgery to increase the chances of treatment success.


'/>"/>

Contact: Donna Dubuc
donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert  

Related biology news :

1. Dartmouth-led research shows temperature, not snowfall, driving tropical glacier size
2. Dartmouth study shows US Southwest irrigation system facing decline after 4 centuries
3. Dartmouth researchers develop new tool to identify genetic risk factors
4. Dartmouth-led team gets $8 million grant to research arsenic in children
5. Dartmouth-led study shows diet alone can be significant source of arsenic
6. Dartmouth-led team discovers how plants avoid sunburn
7. Dartmouth researchers find there is no single sexy chin
8. Dartmouth researchers invent real time secondhand smoke sensor
9. Dartmouth neuroscientist finds free will has neural basis
10. Dartmouth research offers new control strategies for bipolar bark beetles
11. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dartmouth researchers find promising results with local hyperthermia of tumors
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... ... March 01, 2017 , ... Ace Laboratories, ... into clinical applications, announces the formation of its Scientific and Clinical Advisory Board. ... the drug which has been discussed in the media as “the red wine ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
(Date:2/28/2017)... NEW YORK , Feb. 28, 2017 /PRNewswire/ ... company, announced today the formation of the Phosphorus ... and science experts chosen to advise the company ... company,s large-scale, multi-site research initiatives. Please visit ... team and initiatives. "We,ve gathered some ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology: